Omega-3 and immunotherapy for stage ii or iii stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking an omega-3 supplement (like fish oil) alongside standard immunotherapy can help people with stage II or III stomach cancer. The goal is to see if adding omega-3 makes the treatment work better and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of stomach cancer or where the stomach meets the food pipe, at stage II or III.
- You must be relatively active and able to care for yourself (ECOG score 0-2).
- You must have adequate organ function, as shown by blood tests.
- You must not have had prior chemotherapy, radiation, or immunotherapy for this cancer.
- You must not have another active cancer (except certain skin or cervical cancers) in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This clinical trial tests whether adding an immunotherapy drug called tislelizumab to chemotherapy before surgery is better than chemotherapy alone for people with a certain type of stomach cancer. The goal is to see if the combination helps shrink the tumor and improves the chance of successful surgery.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy after surgical removal of stomach cancer can prevent the cancer from returning in older adults (aged 65 and above). The study aims to see if this combination improves outcomes compared to chemotherapy alone.
Hear when a new Gastric Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.